Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial

Hiroyuki Takashima, Yoshinori Yoshida, Chinami Nagura, Tetsuya Furukawa, Ritsukou Tei, Takashi Maruyama, Noriaki Maruyama, Masanori Abe
  • Diabetes and Vascular Disease Research, June 2018, SAGE Publications
  • DOI: 10.1177/1479164118782872
The author haven't yet claimed this publicationThe author haven't yet claimed this publication
Read Publication

http://dx.doi.org/10.1177/1479164118782872

In partnership with: